Peregrine Capital Management LLC lessened its position in Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 12.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,887 shares of the company’s stock after selling 34,646 shares during the quarter. Peregrine Capital Management LLC owned about 1.02% of Tabula Rasa HealthCare worth $12,910,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TRHC. Macquarie Group Ltd. lifted its position in Tabula Rasa HealthCare by 29.3% during the fourth quarter. Macquarie Group Ltd. now owns 1,002,296 shares of the company’s stock worth $48,792,000 after buying an additional 227,187 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Tabula Rasa HealthCare by 125.2% during the first quarter. Bank of New York Mellon Corp now owns 733,507 shares of the company’s stock worth $38,354,000 after buying an additional 407,738 shares in the last quarter. William Blair Investment Management LLC lifted its position in Tabula Rasa HealthCare by 20.0% during the first quarter. William Blair Investment Management LLC now owns 631,336 shares of the company’s stock worth $33,013,000 after buying an additional 105,212 shares in the last quarter. State Street Corp lifted its position in Tabula Rasa HealthCare by 8.1% during the first quarter. State Street Corp now owns 615,488 shares of the company’s stock worth $32,184,000 after buying an additional 46,305 shares in the last quarter. Finally, First Trust Advisors LP raised its position in Tabula Rasa HealthCare by 49.3% in the second quarter. First Trust Advisors LP now owns 591,869 shares of the company’s stock valued at $32,393,000 after purchasing an additional 195,394 shares during the period.

A number of research firms have commented on TRHC. ValuEngine upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Tuesday, July 7th. Benchmark reduced their target price on Tabula Rasa HealthCare from $90.00 to $84.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Royal Bank of Canada began coverage on Tabula Rasa HealthCare in a research report on Monday, April 20th. They issued an “outperform” rating and a $70.00 target price on the stock. Finally, BidaskClub downgraded Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $68.91.

In related news, Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $55.02, for a total transaction of $55,020.00. Following the completion of the transaction, the director now directly owns 12,989 shares of the company’s stock, valued at approximately $714,654.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $60.09, for a total value of $480,720.00. Following the transaction, the president now directly owns 751,701 shares of the company’s stock, valued at $45,169,713.09. The disclosure for this sale can be found here. Insiders have sold a total of 43,260 shares of company stock valued at $2,532,750 over the last three months. 11.60% of the stock is currently owned by insiders.

TRHC traded down $0.24 on Friday, hitting $56.20. 212,480 shares of the company were exchanged, compared to its average volume of 215,383. Tabula Rasa HealthCare Inc has a twelve month low of $33.04 and a twelve month high of $69.72. The company has a current ratio of 2.32, a quick ratio of 2.20 and a debt-to-equity ratio of 1.40. The firm has a 50-day moving average price of $56.43 and a two-hundred day moving average price of $56.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.24. Tabula Rasa HealthCare had a negative return on equity of 3.01% and a negative net margin of 12.10%. The firm had revenue of $72.80 million during the quarter, compared to analysts’ expectations of $71.76 million. During the same period in the previous year, the firm posted $0.10 EPS. Tabula Rasa HealthCare’s revenue for the quarter was up 19.3% on a year-over-year basis. Sell-side analysts expect that Tabula Rasa HealthCare Inc will post -0.28 earnings per share for the current fiscal year.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: Market Capitalization and Individual Investors

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.